Genetic testing is now a cornerstone of modern oncology, enabling clinicians to identify inherited (germline) mutations such as BRCA1/2, TP53, and Lynch‑syndrome genes, as well as somatic alterations that guide targeted therapies and immunotherapy. In India, hereditary cancer syndromes remain markedly under‑diagnosed because of limited access to affordable, accredited genetic services, leading many high‑risk families to miss preventive surveillance and risk‑reducing options. Agam Diagnostics addresses this gap by offering comprehensive medical‑genetics testing—including multigene panels for hereditary risk and tumor DNA profiling—through free home collection, rapid 7‑10‑day turnaround, and full NABL and ICMR accreditation, ensuring high‑quality, reliable results for clinicians and patients alike. These services empower patients to receive surveillance schedules, prophylactic interventions, and eligibility for targeted drugs, ultimately improving outcomes.
Germline (inherited) genetic testing examines DNA from blood or saliva to identify pathogenic variants such as BRCA1/2, TP53, or Lynch‑syndrome genes that raise a person’s lifetime cancer risk. Results guide personalized surveillance, risk‑reducing surgery, and cascade testing of relatives. Somatic testing analyzes DNA extracted from a cancer biopsy or liquid biopsy to detect acquired mutations—e.g., EGFR, KRAS, BRAF, HER2—that drive tumor growth and predict response to targeted therapies or immunotherapies. Clinically, germline testing informs preventive strategies and may uncover eligibility for drugs like PARP inhibitors, while somatic testing directs treatment choices for the current disease, such as EGFR inhibitors in lung cancer or HER2‑targeted therapy in breast cancer. The two approaches are complementary: a somatic panel can reveal a germline‑relevant mutation, prompting germline confirmation, and germline results can affect therapy decisions (e.g., avoiding radiation in TP53 carriers). Together they enable a precision‑medicine workflow that spans risk assessment, early detection, and individualized treatment.
Genetic counseling is a cornerstone of cancer risk management. Pre‑test risk assessment begins with a detailed three‑generation family history, personal cancer diagnoses, and clinical factors (e.g., early‑onset disease, multiple tumor types) to determine eligibility for germline testing and to select the most relevant gene panel. Interpretation of results is performed by certified counselors who classify findings as pathogenic, likely pathogenic, variant of uncertain significance, or negative, and explain how each category influences surveillance, prophylactic surgery, or targeted therapy (e.g., PARP inhibitors for BRCA‑mutated tumors). Psychosocial support addresses anxiety, potential stigma, and ethical concerns, providing coping strategies and clear communication about insurance protection under regulations such as GINA. Finally, family cascade testing is offered to at‑risk relatives, enabling early detection and preventive interventions across the family unit. Accredited laboratories like Agam Diagnostics (NABL, ICMR) ensure high‑quality results, while free home collection and rapid turnaround facilitate timely counseling and clinical decision‑making.
Companion diagnostic tests pair a specific biomarker assay with an FDA‑approved drug to predict therapeutic effectiveness, turning tumor molecular profiling into a decision‑making tool. Common actionable mutations identified by biomarker testing include EGFR, ALK, KRAS, BRAF, HER2, BRCA1/2, and MSI‑H, each linked to a targeted therapy such as EGFR inhibitors, ALK inhibitors, PARP inhibitors, or HER2‑directed antibodies. Detecting these alterations guides clinicians in selecting the most appropriate regimen—often sparing patients from ineffective chemotherapy and reducing toxicity. Moreover, biomarker results determine eligibility for clinical trials, including basket or umbrella studies, where patients receive novel agents matched to their tumor’s genetic makeup. By integrating companion diagnostics, actionable mutation panels, and trial enrollment criteria, biomarker testing enables truly personalized oncology care.
Individuals who test positive for hereditary cancer mutations benefit from tailored surveillance, prophylactic interventions, chemoprevention, and cascade testing of relatives. Screening schedules are intensified: BRCA1/2 carriers begin annual breast MRI (and mammography after age 30) and ovarian ultrasound or CA‑125 monitoring starting at 35‑40 years, while Lynch‑syndrome carriers undergo colonoscopy every 1–2 years beginning at 20‑25 years and consider endometrial sampling. Prophylactic surgeries offer risk‑reducing options—bilateral mastectomy and salpingo‑oophorectomy dramatically lower breast and ovarian cancer incidence in BRCA mutation carriers, and total colectomy reduces colorectal cancer in high‑penetrance MMR gene families. Chemoprevention, such as tamoxifen for BRCA‑positive women or aspirin for Lynch‑syndrome patients, further attenuates risk. Finally, cascade testing of first‑degree relatives identifies additional mutation carriers, enabling early entry into these surveillance and preventive programs and extending the benefit of the index patient’s genetic insight to the entire family.
Agam Diagnostics, a fully automated pathology laboratory in Madurai, Tamil Nadu, India, combines rigorous accreditation with patient‑centric logistics to provide reliable genetic testing for cancer risk and treatment. The laboratory is accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL) and the Indian Council of Medical Research (ICMR), guaranteeing compliance with international quality standards, reproducible results, and secure data handling. To remove geographic barriers, Agam offers free home collection of blood or saliva samples, allowing patients in remote or underserved areas to access testing without traveling to a clinic. Once the specimen arrives, next‑generation sequencing (NGS) panels are run on a high‑throughput, fully automated platform, delivering comprehensive analysis of 40‑plus cancer‑related genes within 7‑10 days—a rapid turnaround that supports timely clinical decision‑making. Throughout the process, certified genetic counselors interpret results, explain their clinical significance, and guide patients and their families on surveillance, risk‑reduction, and therapeutic options, ensuring that each test translates into actionable, personalized care.
Awareness and education remain the first hurdle; many Indian patients are unaware that 5‑10 % of cancers are hereditary and that testing can guide both prevention and therapy. Community outreach and training of primary‑care physicians can improve referral rates, especially when family‑history questionnaires are used to identify high‑risk individuals. Cultural stigma surrounding cancer and genetic disease often discourages discussion of hereditary risk. Certified genetic counselors can provide culturally sensitive counseling that addresses fears of discrimination and promotes informed decision‑making. Insurance coverage varies widely, but guidelines from NCCN and ASCO recommend reimbursement for germline panels when clinical criteria are met; clear communication between oncologists, counselors, and insurers can increase approval rates. Finally, infrastructure and access are expanding through initiatives such as Agam Diagnostics, which offers free home collection, rapid 7‑10‑day turnaround, and NABL/ICMR‑accredited testing, thereby reaching rural populations and reducing logistical barriers.
Liquid biopsy offers a minimally invasive way to capture circulating tumor DNA (ctDNA), enabling real‑time monitoring of tumor evolution, early detection of resistance mutations, and access to profiling when tissue is scarce. Coupled with high‑throughput next‑generation sequencing, it can reveal actionable alterations such as EGFR T790M or BRCA reversion mutations, guiding timely therapy switches. Artificial intelligence accelerates the interpretation of these complex genomic datasets, flagging clinically relevant variants, predicting tumor mutational burden, and integrating multi‑omics signals to prioritize treatment options. AI‑driven platforms also streamline patient matching for basket trials, where enrollment is based on a shared biomarker—regardless of tumor site—expanding access to targeted agents for rare alterations like NTRK fusions or high microsatellite instability. Emerging biomarkers, including tumor‑derived exosomal RNA, epigenetic signatures, and proteomic panels, promise to refine risk stratification and therapeutic selection, further cementing liquid biopsy, AI, and adaptive trial designs as pillars of next‑generation precision oncology.
Genetic testing delivers concrete benefits: it pinpoints inherited cancer‑predisposition mutations (e.g., BRCA1/2, Lynch genes), enables earlier, intensified surveillance, informs risk‑reducing surgeries, and guides tumor‑targeted therapies such as PARP or EGFR inhibitors. Patients with strong family histories, early‑onset disease, or rare syndromes should discuss testing with a certified genetic counselor, and providers must integrate testing into routine oncology workflows. Timely ordering of germline and somatic panels—ideally through accredited facilities—guarantees reliable, high‑quality results that meet international standards (NABL, ICMR). Accredited labs such as Agam Diagnostics offer free home collection and rapid turnaround, removing barriers and ensuring that accurate DNA insights translate into personalized prevention and treatment plans.
The rapid expansion of cellular therapies, from CAR‑T cells (liso‑cel, ide‑cel) to bispecific antibodies, is reshaping treatment algorithms for B‑cell lymphomas, follicular lymphoma, and CNS‑involved myeloma, delivering response rates up 85% and durable remissions. Simultaneously, automation and AI‑driven hematology analyzers—integrating laser‑based flow cytometry, digital morphology, and machine‑learning flagging—are cutting turnaround times to minutes, enabling real‑time MRD monitoring and early detection of abnormal cells. Precision medicine is now anchored by comprehensive genomic profiling via next‑generation sequencing panels that uncover actionable mutations (e.g., BTK, BCL‑2, JAK‑STAT) and guide targeted regimens such as acalabrutinib + venetoclax or pelabresib + ruxolitinib. Together, these advances create a seamless pipeline from rapid, AI‑enhanced diagnostics to personalized, cellular‑based therapeutics, accelerating outcomes for patients with hematologic disorders.
In 2024, CAR‑T and bispecific modalities are shifting from salvage to frontline use. Real‑world CIBMTR data (n = 156) showed lisocabtagene maraleucel (liso‑cel; Breyanzi) achieved a 6‑month PFS of 61 % and OS of 87 % as second‑line therapy for relapsed/refractory large B‑cell lymphoma, while the ELARA phase‑2 update reported tisagenlecleucel with a 4‑year OS of 79.3 % and a 69.1 % CR rate in follicular lymphoma. Dual‑target CD20/CD19 antibodies further lowered progression and death risk in follicular lymphoma (ASH LBA‑1). Bispecific T‑cell engagers are also delivering striking results: blinatumomab raised three‑year disease‑free survival to 97 % in pediatric B‑ALL, and epcoritamab produced a 61 % overall response rate in relapsed/refractory CLL after BTK and BCL‑2 inhibitor failure. These outcomes underscore the expanding role of immunotherapy earlier in treatment algorithms.
Mindray’s newest hematology analyzers marry laser‑based flow cytometry, impedance and fluorescence to generate detailed cell morphology, Immature Platelet Fraction (IPF) and optical platelet counts in seconds. The integrated AI algorithms automatically flag abnormal cells, calculate derived parameters such as Reticulocyte Hemoglobin (RET‑He) and inflammation ratios, and dramatically cut the need for manual slide review. In parallel, digital morphology platforms like Mindray’s MC‑80 scan peripheral‑smear slides, apply deep‑learning models to detect blasts, atypical lymphocytes and other subtle changes, and feed the results directly into the laboratory information system. Agam Diagnostics in Madurai has built a fully automated, 24‑hour workflow around these technologies, offering free home collection, NABL and ICMR accreditation, and a turnaround‑ under 24 hours for complete blood counts and specialized hematology panels. Together, AI‑driven analysis and end‑to‑end automation are reshaping laboratory hematology by delivering faster, more accurate diagnoses while freeing technologists for higher‑value tasks.
Comprehensive next‑generation sequencing (NGS) panels have become a cornerstone of modern hematology, especially for AML, MDS, and CLL. By simultaneously detecting mutations in genes such as FLT3, NPM1, DNMT3A, IDH1/2, and a broad array of epigenetic regulators, NGS enables clinicians to match patients with targeted agents and determine eligibility for novel therapies. In acute myeloid leukemia, the molecular risk signature (mPRS) stratifies individuals receiving hypomethylating agents plus venetoclax into three outcome groups, guiding intensity of treatment and informing prognosis. In mantle‑cell lymphoma, NGS‑enhanced minimal residual disease (MRD) assessment allows treatment de‑escalation, permitting omission of high‑dose chemotherapy and autologous stem‑cell transplant without compromising long‑term survival. These advances illustrate how NGS directly influences treatment selection, risk stratification, and therapeutic de‑intensification across hematologic malignancies.
Oral agents are reshaping chronic lymphocytic leukemia (CLL) management. Five‑year SEQUOIA data demonstrate that zanubrutinib (Brukinsa) delivers superior progression‑free survival and a more favorable safety profile than bendamustine‑rituximab in treatment‑naïve CLL/SLL, establishing it as a new standard of care. The AMPLIFY phase‑3 trial showed that a fixed‑duration, all‑oral regimen of acalabrutinib plus venetoclax (doublet) achieved an 83.1% 36‑month PFS, markedly outpacing standard chemo‑immunotherapy. Emerging BTK degraders, exemplified by BGB‑16673, have reported an overall response rate of ~78% in relapsed/refractory CLL, offering a strategy to overcome resistance to conventional BTK inhibitors. Together, these oral therapies and novel degraders are redefining the CLL treatment paradigm by providing highly effective, chemotherapy‑free options with durable responses and improved tolerability.
Recent advances have turned gene‑editing into a realistic cure for hemoglobin disorders. Exagamglogene autotemcel (Exa‑cel) became the first FDA‑approved ex vivo CRISPR‑Cas9 therapy for sickle cell disease, editing the BCL11A enhancer in autologous hematopoietic stem cells to reactivate fetal hemoglobin and achieve durable transfusion‑independence. Lovotibeglogene autotemcel, a lentiviral vector that adds a functional β‑globin gene (HbAT87Q), received approval for sickle cell disease and expands the curative toolkit for both sickle cell and β‑thalassemia. Parallel pre‑clinical work is testing in‑vivo CRISPR delivery—using adeno‑associated viral capsids or lipid‑nanoparticle carriers—to edit hematopoietic stem cells directly in patients, which could eliminate the need for cell collection and ex‑vivo manipulation. These milestones collectively illustrate that precise genome‑editing is rapidly moving from experimental to therapeutic reality for hemoglobinopathies.
Non‑pharmacologic factors are emerging as powerful modifiers of hematologic outcomes. Current pre‑clinical data (ASH abstract 259) show that higher dietary fiber intake after allogeneic stem‑cell transplantation attenuates gastrointestinal graft‑versus‑host disease and translates into better overall survival, likely through modulation of gut microbiota and inflammatory pathways. Conversely, smoking exerts a dose‑responsive increase in somatic mutational burden, accelerating the evolution of myelodysplastic syndrome to acute myeloid leukemia (ASH abstract 4597, underscoring the need for aggressive smoking cessation programs in at‑risk populations. In mantle‑cell lymphoma, minimal residual disease (MRD) monitoring now guides treatment de‑escalation: patients with MRD‑negative status can safely skip high‑dose chemotherapy and autologous stem‑cell transplant without compromising long‑term survival (ASH abstract LBA‑6. Together, these findings highlight how lifestyle interventions and MRD‑driven decision‑making can personalize care, reduce treatment toxicity, and improve survival across diverse hematologic diseases.
Automated laboratories such as Agam Diagnostics are already delivering cutting‑edge haematology testing—AI‑driven differential counts, rapid CBCs, and advanced flow‑cytometry panels—within 24 hours while offering free home collection and NABL/ICMR‑accredited quality. Scaling these capabilities nationwide will help India’s 1.5 million‑strong Madurai region and other underserved areas access molecular panels, MRD monitoring, and NGS‑based mutation profiling essential for personalized therapy. Equitable distribution of novel agents—CAR‑T cells, bispecific antibodies, oral BTK degraders, and next‑generation gene‑editing treatments—requires public‑funded reimbursement, regional trial sites, and tele‑pathology networks. Looking forward, AI‑assisted diagnostics, CRISPR‑based curative approaches, and fixed‑duration oral regimens (e.g., acalabrutinib + venetoclax) will further bridge the gap between breakthrough science and everyday patient care across India.
Agam Diagnostics
Opp. To Gover.
Super Specialty Hospital,,
Tirunelveli - 627011,
Tamil Nadu, India
Agam Diagnostics
4A, 3, 10th Cross St,
Thillai Nagar East,
Thillai Nagar,
Tiruchirappalli - 620018
Tamil Nadu, India
Agam Diagnostics
#21, Dhali Road,
Udumalpet-642126.
Tirupur District.
Tamil Nadu, India
